# US 2010/0168016 A1 · Diagnosis and treatment of diseases caused by misfolded proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168016 A1
- Document ID: US20100168016A1
- Status: Published application
- Kind: A1
- Application number: 12/593,988
- Filed: 2008-04-11
- Published: 2010-07-01
- Earliest claimed: 2007-04-11
- Assignees: The Jackson Laboratory
- Inventors: Susan Ackerman; Jeong Wong Lee
- Web page: https://patentgrep.com/patent/US20100168016A1

## CPC

- C07K 14/47: from mammals
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/18: against material from animals or humans
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

In certain aspects, the disclosure relates to methods and compositions for diagnosing and treating diseases caused by misfolded proteins that comprise monitoring ANKRD 16 expression and altering the activity of ANKRD 16 protein. In certain embodiments, the diseases are neurodegenerative diseases. In certain embodiments, the diseases are proteopathies. In certain embodiments, the disease is reduced fertility. Methods for identifying agents that protect against cell death are also provided.

## Claims

### Claim at position 1

1-115. (canceled)

### Claim 116

A method of treating a neurodegenerative disease or a proteopathy, the method comprising administering to a subject in need thereof an effective amount of a composition comprising ANKRD16 protein or a nucleic acid encoding ANKRD16.

### Claim 117 (depends on 1)

The method of claim 1, wherein the ANKRD16 protein is selected from SEQ ID Nos: 2, 4, 6, 8, 10, 12, 14 or 22.

### Claim 118 (depends on 1)

The method of claim 1, wherein a neurodegenerative disease is selected from the group consisting of: Alexander disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, Ataxia telangiectasia, Batten disease, Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington disease, HIV-associated dementia, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado-Joseph disease, Multiple sclerosis, Multiple System Atrophy, Parkinson disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Refsum's disease, Sandhoff disease, Schilder's disease, Schizophrenia, Spielmeyer-Vogt-Sjogren-Batten disease, Spinocerebellar ataxia, Spinal muscular atrophy, Steele-Richardson-Olszewski disease, and Tabes dorsalis.

### Claim 119 (depends on 1)

The method of claim 1, wherein the proteopathy is selected from the group consisting of: infertility, reduced fertility, cancer, Hereditary lattice corneal dystrophy, cataracts, myopathy, amyloidosis, diabetes, medullary thyroid carcinoma, Pituitary prolactinoma, and Pulmonary alveolar proteinosis.

### Claim 120 (depends on 1)

The method of claim 1, wherein the said composition is administered systemically or locally.

### Claim 121 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 122 (depends on 1)

The method of claim 1, wherein said composition promotes neuronal cell survival.

### Claim 123 (depends on 1)

The method of claim 1, wherein said composition is formulated with a pharmaceutically acceptable carrier.

### Claim 124 (depends on 1)

The method of claim 1, further comprising at least one additional therapeutic for a neurodegenerative disease or a proteopathy.

### Claim 125

A method of detecting whether a subject has or is at risk of developing a neurodegenerative disease or a proteopathy, comprising:
(a) contacting a sample obtained from said subject with at least one probe that binds at least one ANKRD16 isoform; and
(b) assessing the presence of full-length and short ANKRD16 isoforms, wherein the presence of higher amounts of short ANKRD16 isoforms compared to the full-length ANKRD16 isoform is indicative that the subject has or is at risk of developing a neurodegenerative disease or a proteopathy.

### Claim 126 (depends on 125)

The method of claim 125, wherein said probe is selected from the group consisting of an antibody or antigen binding fragment thereof, a non-immunoglobulin antigen-binding scaffold, and a nucleic acid.

### Claim 127 (depends on 125)

The method of claim 125, wherein said isoform is selected from the group consisting of protein or RNA isoforms.

### Claim 128 (depends on 125)

The method of claim 125, wherein said subject is a human.

### Claim 129 (depends on 125)

The method of claim 125, wherein said neurodegenerative disease is selected from the group consisting of: Alexander disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, Ataxia telangiectasia, Batten disease, Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington disease, HIV-associated dementia, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado-Joseph disease, Multiple sclerosis, Multiple System Atrophy, Parkinson disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Refsum's disease, Sandhoff disease, Schilder's disease, Schizophrenia, Spielmeyer-Vogt-Sjogren-Batten disease, Spinocerebellar ataxia, Spinal muscular atrophy, Steele-Richardson-Olszewski disease, or Tabes dorsalis.

### Claim 130 (depends on 125)

The method of claim 125, wherein the proteopathy is selected from the group consisting of: infertility, reduced fertility, cancer, Hereditary lattice corneal dystrophy, cataracts, myopathy, amyloidosis, diabetes, medullary thyroid carcinoma, Pituitary prolactinoma, and Pulmonary alveolar proteinosis.

### Claim 131

A kit for diagnosis or prognosis of a neurodegenerative disease or a proteopathy comprising at least one probe that binds at least one ANKRD16 isoform, a detectable label, and instructions for using the kit, wherein said probe is selected from the group consisting of an antibody or antigen binding fragment thereof or a nucleic acid.

### Claim 132

A device for detecting whether a subject has or is at risk of developing a neurodegenerative disease or proteopathy comprising a solid matrix and an ANKRD16 probe deposited on said solid support matrix, wherein said probe facilitates the measurement of the level of ANKRD16 in a test sample.

### Claim 133 (depends on 132)

The device of claim 132, wherein the ANKRD16 probe is an antibody or antigen binding fragment or non-immunoglobulin antigen-binding scaffold, which specifically binds ANKRD16 protein to form an antibody or antigen binding-ANKRD16 protein complex.

### Claim 134 (depends on 132)

The device of claim 132, wherein the solid matrix is a dipstick, bead, or a microtiter plate.
